8,211 Shares in United Therapeutics Corporation $UTHR Bought by First National Bank of Omaha

First National Bank of Omaha bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 8,211 shares of the biotechnology company’s stock, valued at approximately $3,442,000.

Other large investors have also recently bought and sold shares of the company. Bessemer Group Inc. lifted its stake in shares of United Therapeutics by 2.6% in the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after purchasing an additional 28 shares during the period. Archer Investment Corp increased its holdings in United Therapeutics by 9.5% in the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 31 shares in the last quarter. F m Investments LLC increased its holdings in United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after purchasing an additional 33 shares in the last quarter. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the period. Finally, Coldstream Capital Management Inc. boosted its holdings in shares of United Therapeutics by 2.0% during the 2nd quarter. Coldstream Capital Management Inc. now owns 2,145 shares of the biotechnology company’s stock worth $616,000 after buying an additional 43 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on UTHR. Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Wells Fargo & Company increased their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Finally, Morgan Stanley set a $447.00 price target on United Therapeutics in a report on Wednesday, October 29th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Price Performance

UTHR opened at $482.42 on Wednesday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $519.99. The firm has a market capitalization of $20.77 billion, a PE ratio of 18.28, a P/E/G ratio of 2.52 and a beta of 0.85. The company’s 50-day moving average is $486.02 and its 200 day moving average is $437.28.

Insider Activity

In related news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $479.91, for a total value of $10,797,975.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 450,714 shares of company stock worth $218,011,238 over the last 90 days. 10.30% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.